.png "Cytosorbents Corp (NASDAQ: CTSO)")
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Cytosorbents Corp (NASDAQ: CTSO) today and set a price target of $14. The company’s shares closed yesterday at $8.05, close to its 52-week high of $8.35.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 4.3% and a 35.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
Currently, the analyst consensus on Cytosorbents Corp is Strong Buy and the average price target is $12, representing a 49.1% upside.
In a report issued on April 24, Maxim Group also maintained a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.35 and a one-year low of $3.30. Currently, Cytosorbents Corp has an average volume of 190.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytoSorbents Corp. engages in the development blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product, CytoSorb, is a extracorporeal cytokine filter and seeks to reduce cytokine storm that could otherwise cause massive inflammation, organ failure, and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
